Director of the Michigan Center for Translational Pathology S.P. Hicks Endowed Professor of Pathology and Urology Investigator, Howard Hughes Medical Institute
Pathology
Dr. Arul M. Chinnaiyan, MD
|
|
Give Review
Arul Chinnaiyan is an expert in the field of Pathology. He studied medicine at University of Michigan Medical School. He received 3 awards: "Elected Member", "Investigator" and "Whos Who in Medicine and Healthcare". Doctor Arul M. Chinnaiyan, MD is a published doctor and has 100 publications published. The lastest was: 'Prognostic value of percent Gleason grade 4 at prostate biopsy on predicting prostatectomy pathology and recurrence.'
Publications
- Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.
- Comprehensive Immunophenotypic Characterization of Adult and Fetal Testes, the Excretory Duct System, and Testicular and Epididymal Appendages.
- Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer.
- Prognostic value of percent Gleason grade 4 at prostate biopsy on predicting prostatectomy pathology and recurrence.
- KRAS Engages AGO2 to Enhance Cellular Transformation.
- A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall.
- Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.
- aBETting therapeutic resistance by Wnt signaling.
- Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PC...
- Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.
- Translating cancer genomes and transcriptomes for precision oncology.
- Two-Pass Alignment Improves Novel Splice Junction Quantification.
- ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients.
- The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.
- Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma.
- Targeting the MLL complex in castration-resistant prostate cancer.
- The landscape of long noncoding RNAs in the human transcriptome.
- 26th Pezcoller Symposium: Cancers Driven by Hormones.
- rSeqNP: a non-parametric approach for detecting differential expression and splicing from RNA-Seq data.
- Active surveillance for prostate cancer: the role of the pathologist.
- A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate ...
- RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
- RNA-Seq Accurately Identifies Cancer Biomarker Signatures to Distinguish Tissue of Origin.
- The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc.
- The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement wi...
- Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.
- Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
- HRAS mutations are frequent in inverted urothelial neoplasms.
- Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
- Novel RNA Hybridization Method for the In Situ Detection of ETV1, ETV4, and ETV5 Gene Fusions in Prostate Cancer.
- Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.
- The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
- Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant pros...
- BETs abet Tam-R in ER-positive breast cancer.
- Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings.
- The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer.
- BETting on a new prostate cancer treatment.
- Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.
- Molecular Pathways: Targeting ETS Gene Fusions in Cancer.
- HOXB13 G84E-related Familial Prostate Cancers: A Clinical, Histologic, and Molecular Survey.
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
- The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.
- RNA Identity Crisis: Hepatitis B Walks the LINE.
- KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation.
- Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.
- Primary Urethral Clear-Cell Adenocarcinoma: Comprehensive Analysis by Surgical Pathology, Cytopathology, and Next-Generation Sequencing.
- The central role of EED in the orchestration of polycomb group complexes.
- Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer.
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
- Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition.
- The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T cell responses mediating graft-versus-host disease.
- The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.
- Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG.
- Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification.
- HR-MAS NMR Tissue Metabolomic Signatures Cross-validated by Mass Spectrometry Distinguish Bladder Cancer from Benign Disease.
- Usefulness of a Monoclonal ERG/FLI1 Antibody for Immunohistochemical Discrimination of Ewing Family Tumors.
- HIV Infection Reveals Wide-Spread Expansion of Novel Centromeric Human Endogenous Retroviruses.
- The role of sarcosine metabolism in prostate cancer progression.
- Advancing Precision Medicine for Prostate Cancer Through Genomics.
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers.
- Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy.
- Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.
- Next-Generation Sequencing Identifies the Danforth's Short Tail Mouse Mutation as a Retrotransposon Insertion Affecting Ptf1a Expression.
- Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.
- MicroRNA expression patterns in indeterminate inflammatory bowel disease.
- Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
- Dual Roles of PARP-1 Promote Cancer Growth and Progression.
- MetaboID: A graphical user interface package for assignment of (1)H NMR spectra of bodyfluids and tissues.
- A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature.
- Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
- Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.
- Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.
- Systematic, evidence-based discovery of biomarkers at the NCI.
- Analysis of the Tau-Associated Proteome Reveals That Exchange of Hsp70 for Hsp90 Is Involved in Tau Degradation.
- The mutational landscape of lethal castration-resistant prostate cancer.
- SLC45A3-ELK4 Chimera in Prostate Cancer: Spotlight on cis-Splicing.
- Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A(2), a potential therapeutic target.
- Expressed pseudogenes in the transcriptional landscape of human cancers.
- Variable reference alignment: an improved peak alignment protocol for NMR spectral data with large intersample variation.
- The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells.
- Insights into Chinese prostate cancer with RNA-seq.
- Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target.
- Common Structural and Epigenetic Changes in the Genome of Castration Resistant Prostate Cancer.
- Personalized oncology through integrative high-throughput sequencing: a pilot study.
- Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.
- Magic Angle Spinning NMR Based Metabolic Profiling of Head and Neck Squamous Cell Carcinoma Tissues.
- The emergence of lncRNAs in cancer biology.
- Common Gene Rearrangements in Prostate Cancer.
- Coordinated regulation of polycomb group complexes through microRNAs in cancer.
- ChimeraScan: A tool for identifying chimeric transcription in sequencing data.
- Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
- Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.
- TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
- Characterization of KRAS Rearrangements in Metastatic Prostate Cancer.
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
- Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
- Characterization of bone metastases from rapid autopsies of prostate cancer patients.
- The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity.
Schools
University of Mi Med Sch
Doctors Specialties
- Clinical Pathology
- Pathology
Accepted Insurances
Awards
- Elected Member
- Investigator
- Whos Who in Medicine and Healthcare
Education
-
University of Michigan Hospitals and Health Centers -
University of Michigan Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. David O. Ferguson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexandra C. Hristov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel K. Greenson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rodolfo F. Rasche, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas E. Wilson, MD |
|
|
Dr. Pan Zheng, MD |
|
|
Dr. Michael A. Bachman, MD |
|
|
Dr. Ulysses G. Balis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel F. Boyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristina A. Davis, MD |
|
|
Rohit Mehra, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Pletneva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bun B. Siu, MD |